Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated agelagalastatin
First Claim
Patent Images
1. A cytostatic compound denominated “
- agelagalastatin”
having the following structure;
2 Assignments
0 Petitions
Accused Products
Abstract
A human cancer cell line bioassay-directed investigation of the Western Pacific marine sponge agelas sp. led to isolation of a trace (7.42×10−6% yield) cancer cell growth inhibitor (lung NCI-H460 GI50 0.77 μg/ml to ovary OVCAR-3 GI50 2.8 μg/ml) designated agelagalastatin. Agelagalastatin is the first example of a natural product containing a digalactofuranosyl unit.
3 Citations
3 Claims
-
1. A cytostatic compound denominated “
- agelagalastatin”
having the following structure;
- agelagalastatin”
-
2. The method of treating cells afflicted with neoplastic disease selected from the group consisting of brain, renal, colon cancers and melanoma comprising engaging said cells with an effective amount of agelagalastatin disposed in a pharmacologically acceptable carrier.
-
3. A pharmaceutical preparation for treating neoplastic disease comprising an effective amount of agelagalastatin and a pharmaceutically acceptable carrier.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeArizona Board of Regents (University of Arizona)
-
Original AssigneeArizona Board of Regents (University of Arizona)
-
InventorsXu, Jun-Ping, Pettit, George R.
-
Primary Examiner(s)Jones, Dwayne C.
-
Application NumberUS09/719,082Time in Patent Office264 DaysField of Search514/25, 536/17.4US Class Current514/25CPC Class CodesA61P 35/00 Antineoplastic agentsC07H 15/04 attached to an oxygen atom ...
